RPE65 and respiratory distress syndrome in premature infants: A promising first gene therapy has become available as “Luxturna” (voretigen neparvovec), a treatment for biallelic RPE65-mediated IRDs, was approved in December 2017 in the USA [31] and in November 2018 in Europe [32].